These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 25678490

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E.
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
    Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc'h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E.
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
    [Abstract] [Full Text] [Related]

  • 6. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, Tay KH, Tan BS, Hoe Chow PK, Eng Ng DC, Whatt Goh AS.
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A.
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, Denys A, Prior JO, Baechler S, Boubaker A.
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, Kim E.
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
    Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, Lenoir L, Boudjema K, Ugen T, Brun V, Mesbah H, Haumont LA, Loyer P, Garin E.
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
    [Abstract] [Full Text] [Related]

  • 18. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.
    Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, Wong YH, Leung TWT.
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study.
    Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V, SARAH Trial GroupFrom the Departments of Radiology (A.L.H., M.R., V.V.), Nuclear Medicine (A.D., M.S., R.L.), and Hepatology (L.C.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, 100 boulevard du Général Leclerc, 92110 Clichy, France; Université Paris-Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France (A.L.H., G.C.); INSERM U1149, Centre de Recherche de l'Inflammation (CRI), Paris, France (A.D., M.R., M.S., L.C., R.L., V.V.); Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France (M.R., L.C., R.L., V.V.); Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, Paris, France (H.P., G.C.); INSERM, Centre d'Investigation Clinique 1418 (CIC1418), Paris, France (H.P., G.C.); and Centre Eugène Marquis, Rennes, France (E.G.)..
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.